OPKO Health (NASDAQ:OPK - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $3.00 price target on the biotechnology company's stock. HC Wainwright's target price points to a potential upside of 66.67% from the stock's current price. HC Wainwright also issued estimates for OPKO Health's Q2 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.30) EPS.
Other equities research analysts also recently issued reports about the company. Barrington Research reaffirmed an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a report on Wednesday, March 12th. StockNews.com raised OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd.
View Our Latest Stock Analysis on OPK
OPKO Health Stock Performance
Shares of OPK stock traded down $0.02 during trading hours on Wednesday, hitting $1.80. The stock had a trading volume of 6,950,770 shares, compared to its average volume of 4,335,701. The firm has a market capitalization of $1.21 billion, a PE ratio of -9.47 and a beta of 1.70. OPKO Health has a twelve month low of $0.92 and a twelve month high of $2.04. The stock's 50 day moving average is $1.65 and its 200 day moving average is $1.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.
OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. As a group, research analysts forecast that OPKO Health will post -0.25 earnings per share for the current fiscal year.
Insider Buying and Selling at OPKO Health
In other OPKO Health news, CEO Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock in a transaction on Monday, March 17th. The stock was bought at an average price of $1.74 per share, with a total value of $348,000.00. Following the completion of the acquisition, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. The trade was a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders acquired 964,971 shares of company stock valued at $1,493,692. 47.26% of the stock is owned by company insiders.
Institutional Investors Weigh In On OPKO Health
A number of hedge funds and other institutional investors have recently bought and sold shares of OPK. FMR LLC lifted its holdings in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 11,089 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in shares of OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after buying an additional 12,417 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new position in shares of OPKO Health in the third quarter valued at $45,000. Cibc World Markets Corp purchased a new position in shares of OPKO Health in the fourth quarter valued at $45,000. Finally, Zacks Investment Management purchased a new position in shares of OPKO Health in the fourth quarter valued at $49,000. Institutional investors and hedge funds own 64.63% of the company's stock.
About OPKO Health
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
